Inicio
Información del autor
Autor Luis Vicente Syro Moreno
Comentario :
Médico Neurocirujano, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (77)
Refinar búsqueda
Título : Prolactinomas: diagnosis and treatment Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Expert Review of Endocrinology and Metabolism Idioma : Inglés (eng) Palabras clave : Expert Review of Endocrinology and Metabolism Resumen : Pituitary lactotrophs secrete prolactin. This process is enhanced by estrogen and inhibited by dopamine. Prolactinomas are benign neoplasms that rarely increase in size and are classified according to size as microadenomas (10 mm diameter). The clinical features of prolactinomas most commonly result from prolactin’s effect on the gonads and breast in women and from mass effect in men. This review details the clinical features and management of patients with prolactinomas. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, Luis V Syro, Kalman Kovacs & Ricardo V Lloyd Referencia : Expert Rev Endocrinol Metab. 2012;7(2):233–41. DOI (Digital Object Identifier) : 10.1586/eem.12.4 En línea : https://www.tandfonline.com/doi/full/10.1586/eem.12.4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3605 Prolactinomas: diagnosis and treatment [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Expert Review of Endocrinology and Metabolism
Idioma : Inglés (eng)
Palabras clave : Expert Review of Endocrinology and Metabolism Resumen : Pituitary lactotrophs secrete prolactin. This process is enhanced by estrogen and inhibited by dopamine. Prolactinomas are benign neoplasms that rarely increase in size and are classified according to size as microadenomas (10 mm diameter). The clinical features of prolactinomas most commonly result from prolactin’s effect on the gonads and breast in women and from mass effect in men. This review details the clinical features and management of patients with prolactinomas. Mención de responsabilidad : Farshad Nassiri, Michael D Cusimano, Bernd W Scheithauer, Fabio Rotondo, Alessandra Fazio, Luis V Syro, Kalman Kovacs & Ricardo V Lloyd Referencia : Expert Rev Endocrinol Metab. 2012;7(2):233–41. DOI (Digital Object Identifier) : 10.1586/eem.12.4 En línea : https://www.tandfonline.com/doi/full/10.1586/eem.12.4 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3605 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000175 AC-2012-015 Archivo digital Producción Científica Artículos científicos Disponible Silent somatotroph adenoma: a morphologic, immunohistochemical and electron microscopic study: a case report / Carlos Esteban Builes Montaño ; Luis Vicente Syro Moreno
Título : Silent somatotroph adenoma: a morphologic, immunohistochemical and electron microscopic study: a case report Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, ; Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Journal of Medical Cases Idioma : Inglés (eng) Palabras clave : Electron microscopy histology immunohistochemistry pituitary adenoma endocrine silence Resumen : Pituitary adenoma, removed surgically from a 22 old young man with normal serum growth hormone level, and no evidence of acromegaly by histology, immunohistochemistry and electron microscopy was studied. Ultrastructurally the tumor cells were shown to correspond to sparsely granulated somatotrophs and immunohisto chemistry showed no, moderate, or little growth hormone. Clinically silent somatotroph adenomas so far are unresolved entities; although electron microscopy shows that they are consisted of sparsely granulated somatotrophs they do not secrete substantial amounts to raise growth hormone and IGF-1 blood levels. Further work is required to clarify the mechanisms accounting for the clinical and biochemical silence of these tumors. Mención de responsabilidad : Aydin Sav, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Carlos A Builes, Eva Horvath, Kalman Kovacs Referencia : J Med Cases. 2012;3(1):43-8. DOI (Digital Object Identifier) : 10.4021/jmc416w Derechos de uso : CC BY-NC En línea : https://www.journalmc.org/index.php/JMC/article/view/416 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3612 Silent somatotroph adenoma: a morphologic, immunohistochemical and electron microscopic study: a case report [documento electrónico] / Carlos Esteban Builes Montaño, ; Luis Vicente Syro Moreno, . - 2012.
Obra : Journal of Medical Cases
Idioma : Inglés (eng)
Palabras clave : Electron microscopy histology immunohistochemistry pituitary adenoma endocrine silence Resumen : Pituitary adenoma, removed surgically from a 22 old young man with normal serum growth hormone level, and no evidence of acromegaly by histology, immunohistochemistry and electron microscopy was studied. Ultrastructurally the tumor cells were shown to correspond to sparsely granulated somatotrophs and immunohisto chemistry showed no, moderate, or little growth hormone. Clinically silent somatotroph adenomas so far are unresolved entities; although electron microscopy shows that they are consisted of sparsely granulated somatotrophs they do not secrete substantial amounts to raise growth hormone and IGF-1 blood levels. Further work is required to clarify the mechanisms accounting for the clinical and biochemical silence of these tumors. Mención de responsabilidad : Aydin Sav, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Carlos A Builes, Eva Horvath, Kalman Kovacs Referencia : J Med Cases. 2012;3(1):43-8. DOI (Digital Object Identifier) : 10.4021/jmc416w Derechos de uso : CC BY-NC En línea : https://www.journalmc.org/index.php/JMC/article/view/416 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3612 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000182 AC-2012-022 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2012-022.pdfAdobe Acrobat PDF
Título : Temozolomide in aggressive pituitary adenomas and carcinomas Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : Clinics (Sao Paulo) Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Temozolomide in aggressive pituitary adenomas and carcinomas [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : Clinics (Sao Paulo)
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma MGMT temozolomide review Resumen : Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6 -methylguanine- DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6 -methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6 -methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms. Mención de responsabilidad : Leon D Ortiz, Luis V Syro, Bernd W Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E Fadul, Eva Horvath, Kalman Kovacs Referencia : Clinics. 2012;67(S1):119-23. DOI (Digital Object Identifier) : 10.6061/clinics/2012(Sup01)20 PMID : 22584716 En línea : https://www.revistas.usp.br/clinics/article/view/19731 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3606 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000176 AC-2012-016 Archivo digital Producción Científica Artículos científicos Disponible
Título : Treatment of aggressive pituitary adenomas and carcinomas-An overview Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : US Endocrinology Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma O6-methylguanine-DNA methyltransferase (MGMT) temozolomide everolimus bevacizumab Resumen : Most pituitary tumors are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumors, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation, and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumors and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumors are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs DOI (Digital Object Identifier) : 10.17925/USE.2012.08.01.50 En línea : https://www.touchendocrinology.com/treatment-of-aggressive-pituitary-adenomas-an [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4505 Treatment of aggressive pituitary adenomas and carcinomas-An overview [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : US Endocrinology
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma O6-methylguanine-DNA methyltransferase (MGMT) temozolomide everolimus bevacizumab Resumen : Most pituitary tumors are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumors, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation, and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumors and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumors are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs DOI (Digital Object Identifier) : 10.17925/USE.2012.08.01.50 En línea : https://www.touchendocrinology.com/treatment-of-aggressive-pituitary-adenomas-an [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4505 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001004 AC-2012-093 Archivo digital Producción Científica Artículos científicos Disponible
Título : Treatment of aggressive pituitary adenomas and carcinomas – an overview Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2012 Títulos uniformes : European Neurological Review Idioma : Inglés (eng) Palabras clave : Pituitary adenoma pituitary carcinoma O6-methylguanine-DNA methyltransferase (MGMT) temozolomide everolimus bevacizumab Resumen : Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs Referencia : European Neurological Review. 2012;7(3):178–80. DOI (Digital Object Identifier) : 10.17925/ENR.2012.07.03.178 En línea : https://touchneurology.com/treatment-of-aggressive-pituitary-adenomas-and-carcin [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3630 Treatment of aggressive pituitary adenomas and carcinomas – an overview [documento electrónico] / Luis Vicente Syro Moreno, . - 2012.
Obra : European Neurological Review
Idioma : Inglés (eng)
Palabras clave : Pituitary adenoma pituitary carcinoma O6-methylguanine-DNA methyltransferase (MGMT) temozolomide everolimus bevacizumab Resumen : Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed. Mención de responsabilidad : Luis V Syro, Leon D Ortiz, Fabio Rotondo, Humberto Uribe, Luis C Penagos, Eva Horvath, Kalman Kovacs Referencia : European Neurological Review. 2012;7(3):178–80. DOI (Digital Object Identifier) : 10.17925/ENR.2012.07.03.178 En línea : https://touchneurology.com/treatment-of-aggressive-pituitary-adenomas-and-carcin [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3630 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000200 AC-2012-040 Archivo digital Producción Científica Artículos científicos Disponible PermalinkAggressive silent corticotroph adenoma progressing to pituitary carcinoma : the role of temozolomide therapy / Luis Vicente Syro MorenoPermalinkPermalinkEndoglin (CD105) : a review of its role in angiogenesis and tumor diagnosis, progression and therapy / Luis Vicente Syro MorenoPermalinkPermalinkPermalinkPermalinkPermalinkSomatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation / Luis Vicente Syro Moreno ; Esdras Martín Vásquez MejíaPermalinkPermalink